CI Financial ( TSX: CIX:CA) ( OTCPK:CIXXF) received an interim order from the Ontario Superior Court of Justice that ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

CI shareholders will receive $32.00 in cash per share, representing a 33% premium over the last closing price prior to the announcement of the arrangement and a 58% premium over the 60-day ...

CI Financial receives an interim court order concerning the transaction under which CI shares will be acquired by an affiliate of Mubadala Capital.

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

“Tenvie was purpose-built to apply deep biological and chemical insights to address critical disease pathways,” said Paul L. Berns, Managing Director at ARCH Venture Partners and Executive Chair of ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

The Holdco shares would then be sold to funds managed by Mubadala Capital instead of a direct sale of CI shares (TSX:CIX:CA). Under that plan, the Holdco shares would be sold for the same total ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

has issued an interim order regarding the Corporation’s proposed plan of arrangement (the “Arrangement”) with an affiliate of funds managed by Mubadala Capital (the “Purchaser”) pursuant ...